Immune Mechanisms of Protection against Mycobacterium Tender

• Country: USA
• Summary: Immune Mechanisms of Protection against Mycobacterium Tuberculosis Center Impactb
• UST Ref No: 141551886
• Deadline: 02 Jun 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: BAA-75N93026R00008
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Introduction
  The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. NIAID supports a robust program in basic immunology that includes detailed analyses of human immune responses to pathogenic infections and/or vaccines. NIAID also has a key role in basic, translational and clinical studies to further the understanding of Mycobacterium tuberculosis infection and disease in people living with or without HIV. Furthermore, NIAID provides several resources to the scientific community including testing services of therapeutics, animal models, reagents for research to support biomedical drug, vaccines and diagnostics research.
  The NIAID Divisions of AIDS (DAIDS); Allergy Immunology and Transplantation (DAIT) and Microbiology and Infectious Diseases (DMID) have a joint requirement for the continued support of the Immune Mechanisms of Protection against Mycobacterium tuberculosis center (IMPAc-TB) program to accelerate TB vaccine development through characterization of protective tissue-specific and systemic immune responses that prevent or contain Mtb infection and the advancement of tools and resources to support TB vaccine development. The objective of the IMPAc-TB program renewal is to address these knowledge gaps and accelerate TB vaccine development by supporting research that further characterizes both tissue-specific and systemic protective immune responses, that prevent or contain Mtb infection, and furthers the advancement of tools and resources that facilitate TB vaccine development (e.g., biological models and in vitro systems, computational and modeling platforms). This program will continue to support the co...
• Documents:

 Tender Notice

Documents.zip